BRAF and melanoma: The National Comprehensive Cancer Network (NCCN) guidelines currently recommend pembrolizumab, nivolumab, ipilimumab, or high-dose IL-2 for first-line therapy for metastatic or unresectable BRAF V600 wild-type melanoma (NCCN, 2015).